Quantum Genomics Liabilities 2024

Quantum Genomics Aktienanalyse

What does Quantum Genomics do?

Quantum Genomics SA is a French biotechnology company focused on the discovery and development of novel therapies for the treatment of cardiovascular diseases. The company was founded in 2005 in Grenoble, France, where its headquarters are still located. Over 25 employees are currently working on the development of new drugs. The business model of Quantum Genomics SA is based on the research and development of new and innovative solutions for the cardiovascular disease market. The company focuses on a new class of drugs that target the brain to lower blood pressure and treat certain cardiovascular diseases. The goal of these new therapies is to improve the effectiveness of existing treatment methods by directly addressing the causes of the disease. Quantum Genomics SA has established partnerships with renowned research institutes and universities. The collaboration with these institutions aims to accelerate and intensify the research and development of new drugs. Through this collaboration, the company will be able to develop new solutions and therapies to treat cardiovascular diseases at a faster pace. The company is currently working on two main products: Firibastat and the QT-Glutamylcyclotransferase inhibitor. Firibastat is an oral medication developed for the treatment of hypertension. The QT-Glutamylcyclotransferase inhibitor is another medication that is intended to lower blood pressure. These are promising new solutions that can enable Quantum Genomics SA to play a significant role in the cardiovascular disease market. The products of Quantum Genomics SA aim to treat cardiovascular diseases better and more effectively by directly targeting the brain. This aims to reduce the risk of serious complications and side effects that may occur with conventional medications. In recent years, Quantum Genomics SA has received several awards, including the "Innovation Prize" from the French government. These awards demonstrate that the company is on the right track and achieving its goals. Overall, Quantum Genomics SA has a promising business model based on the development of new therapies for the treatment of cardiovascular diseases. With collaborations with renowned research institutes and the development of promising new products, the company is well-positioned to be successful and make significant progress in the growing market of cardiovascular diseases. Quantum Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Quantum Genomics's Liabilities

Quantum Genomics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Quantum Genomics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Quantum Genomics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Quantum Genomics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Quantum Genomics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Quantum Genomics stock

What is the level of liabilities of Quantum Genomics this year?

Quantum Genomics has a debt balance of 3.31 M EUR this year.

What were the liabilities of Quantum Genomics compared to the previous year?

The liabilities of Quantum Genomics have increased by -83.46% dropped compared to the previous year.

What are the consequences of high debt for investors of Quantum Genomics?

High liabilities can pose a risk for investors of Quantum Genomics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Quantum Genomics?

Low liabilities mean that Quantum Genomics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Quantum Genomics affect the company?

An increase in liabilities of Quantum Genomics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Quantum Genomics affect the company?

A decrease in the liabilities of Quantum Genomics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Quantum Genomics?

Some factors that can influence the liabilities of Quantum Genomics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Quantum Genomics so important for investors?

The liabilities of Quantum Genomics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Quantum Genomics take to modify the liabilities?

To change its liabilities, Quantum Genomics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Quantum Genomics pay?

Over the past 12 months, Quantum Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quantum Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Quantum Genomics?

The current dividend yield of Quantum Genomics is .

When does Quantum Genomics pay dividends?

Quantum Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quantum Genomics?

Quantum Genomics paid dividends every year for the past 0 years.

What is the dividend of Quantum Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quantum Genomics located?

Quantum Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quantum Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quantum Genomics from 11/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Quantum Genomics pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Quantum Genomics in the year 2023?

In the year 2023, Quantum Genomics distributed 0 EUR as dividends.

In which currency does Quantum Genomics pay out the dividend?

The dividends of Quantum Genomics are distributed in EUR.